Back to basics: In search of the optimal dendritic cell for vaccination in AML

Leukemia Research

Volumn 32, Issue 11, 2008, Pages 1641-1643

  van den Ancker, Willemijn ^a   Westers, Theresia M ^a   Ossenkoppele, Gert J ^a   van de Loosdrecht, Arjan A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukemia; Dendritic cell; Immunotherapy

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PREVENTION; DENDRITIC CELL; EDITORIAL; HLA MATCHING; IMMUNE SYSTEM; IMMUNOTHERAPY; LEUKEMIA CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; TUMOR IMMUNITY;

CANCER VACCINES; DENDRITIC CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; VACCINATION;

EID: 47249105077     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.03.029     Document Type: Editorial

References (23)

1. Estey E., and Dohner H. Acute myeloid leukaemia. Lancet 368 (2006) 1894-1907
2. Banchereau J., and Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5 (2005) 296-306
3. Houtenbos I., Westers T.M., Ossenkoppele G.J., and van de Loosdrecht A.A. Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia. Haematologica 91 (2006) 348-355
4. Houtenbos I., Westers T.M., Ossenkoppele G.J., and van de Loosdrecht A.A. Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia. Immunobiology 211 (2006) 677-685
5. Roddie H., Klammer M., Thomas C., Thomson R., Atkinson A., Sproul A., et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol 133 (2006) 152-157
6. Lee J.J., Kook H., Park M.S., Nam J.H., Choi B.H., Song W.H., et al. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J Clin Apher 19 (2004) 66-70
7. Lee J.J., Choi B.H., Kang H.K., Kim S.K., Nam J.H., Yang D.H., et al. Monocyte-derived dendritic cells from HLA-matched allogeneic donors showed a greater ability to induce leukemic cell-specific T cells in comparison to leukemic cell-derived dendritic cells or monocyte-derived dendritic cells from AML patients. Leukemia Res 32 (2008) 1653-1660
8. Ossenkoppele G.J., Stam A.G., Westers T.M., de Gruijl T.D., Janssen J.J., van de Loosdrecht A.A., et al. Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. Leukemia 17 (2003) 1424-1426
9. Houtenbos I., Westers T.M., Hess C.J., Waisfisz Q., Ossenkoppele G.J., and van de Loosdrecht A.A. Flt-3 internal tandem duplication hampers differentiation of AML blasts towards leukemic dendritic cells. Leukemia 20 (2006) 1892-1895
10. Thurner B., Roder C., Dieckmann D., Heuer M., Kruse M., Glaser A., et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 223 (1999) 1-15
11. Kitawaki T., Kadowaki N., Kondo T., Ishikawa T., Ichinohe T., Teramukai S., et al. Potential of dendritic cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole limpet hemocyanin-pulsed, donor-derived dendritic cell vaccine for acute myeloid leukemia. Am J Hematol 83 (2007) 315-317
12. Santegoets S.J., Schreurs M.W., Masterson A.J., Liu Y.P., Goletz S., Baumeister H., et al. In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line. Cancer Immunol Immunother 55 (2006) 1480-1490
13. Hasebe H., Nagayama H., Sato K., Enomoto M., Takeda Y., Takahashi T.A., et al. Dysfunctional regulation of the development of monocyte-derived dendritic cells in cancer patients. Biomed Pharmacother 54 (2000) 291-298
14. Royer P.J., Bougras G., Ebstein F., Leveque L., Tanguy-Royer S., Simon T., et al. Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy. Exp Hematol 36 (2008) 329-339
15. Merrick A., Diaz R.M., O'Donnell D., Selby P., Vile R., and Melcher A. Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naive cytotoxic priming and anti-tumour therapy. Cancer Immunol Immunother 6 (2008) 897-907
16. Banat G.A., Usluoglu N., Hoeck M., Ihlow K., Hoppmann S., and Pralle H. Dendritic cells fused with core binding factor-beta positive acute myeloid leukaemia blast cells induce activation of cytotoxic lymphocytes. Br J Haematol 126 (2004) 593-601
17. Avigan D.E., Vasir B., George D.J., Oh W.K., Atkins M.B., McDermott D.F., et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 30 (2007) 749-761
18. Asavaroengchai W., Kotera Y., and Mule J.J. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci USA 9 (2002) 931-936
19. Schui D.K., Singh L., Schneider B., Knau A., Hoelzer D., and Weidmann E. Inhibiting effects on the induction of cytotoxic T lymphocytes by dendritic cells pulsed with lysates from acute myeloid leukemia blasts. Leukemia Res 6 (2002) 383-389
20. Smits E.L., Ponsaerts P., Van de Velde A.L., Van Driessche A., Cools N., Lenjou M., et al. Proinflammatory response of human leukemic cells to dsRNA transfection linked to activation of dendritic cells. Leukemia 21 (2007) 1691-1699
21. Franki S.N., Steward K.K., Betting D.J., Kafi K., Yamada R.E., and Timmerman J.M. Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B cell lymphoma in vivo. Blood 111 (2007) 1504-1511
22. Houtenbos I., Westers T.M., Dijkhuis A., de Gruijl T.D., Ossenkoppele G.J., and van de Loosdrecht A.A. Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting. Clin Cancer Res 13 (2007) 307-315
23. Houtenbos I, Santegoets SJ, Westers TM, Waisfisz Q, Kipriyanov S, Denkers F, et al. The novel bispecific diabody anti-CD40/anti-CD28 strengthens leukemic dendritic cell induced T cell reactivity. Br J Haematol; in press.